Found 17 matching trials
JSKN003 Combined Treatment of HER2-positive Gastric Cancer PHASE2 This study is designed to evaluate the safety and efficacy of JSKN003 combi...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer PHASE2 This study is designed to compare the efficacy and safety of KN026 combined...
Show More Location
Multiple Locations
Learn More & Join Trial
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer PHASE2 This is an open-lable, multicenter, and single arm phase II trial to evalua...
Show More Location
Fudan University Cancer Hospital
Learn More & Join Trial
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer PHASE1 This is an open-label, phase 1 dose-escalation study of KN026 in subjects w...
Show More Location
Greenville Health System Center Institute
Learn More & Join Trial
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer PHASE1 This is a first-in-human (FIH), open-label, phase 1 dose-escalation study o...
Show More Location
Fudan University Shanghai Cancer Hospital
Learn More & Join Trial
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC PHASE2 This is a multicenter II study to compare KN026 and KN046 versus Oxaliplati...
Show More Location
Beijing Cancer Hospital
Learn More & Join Trial
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer PHASE2 This is an open-label, three-cohort phase 2 study of KN026 in subjects with...
Show More Location
Harbin Medical University Cancer Hospital
Learn More & Join Trial
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. PHASE3 This is a randomized, controlled, open-label, multicenter, phase Ш clinical...
Show More Location
Clinical Trials Information Group
Learn More & Join Trial
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer PHASE3 This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial
KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor PHASE1 This is a phase Ib, open-label, dose-escalation and expansion study to eval...
Show More Location
Beijing Cancer Hospital
Learn More & Join Trial